ClinConnect ClinConnect Logo
Search / Trial NCT06071637

Low Power Laser Therapy As Prevention Of Oral Mucositis And Oropharyngeal Pain In Patients Undergoing Allogenetic HSCT

Launched by INSTITUTO NACIONAL DE CANCER, BRAZIL · Oct 2, 2023

Trial Information

Current as of July 26, 2025

Recruiting

Keywords

Hematopoietic Stem Cell Transplantation Low Level Light Therapy Stomatitis

ClinConnect Summary

This clinical trial is studying a type of treatment called low-power laser therapy to see if it can help prevent oral mucositis (painful sores in the mouth) and throat pain in patients undergoing a procedure known as allogeneic hematopoietic stem cell transplantation (HSCT). The study will compare two different laser therapy methods to determine which one is more effective in reducing these painful side effects. The trial is open to adults over 18 years old who have healthy mouths and are able to follow oral hygiene routines. Participants must also agree to take part in the study.

If you choose to participate, you will receive one of two types of laser treatments starting a week before your transplant and continuing until your bone marrow is collected. The treatments will be performed by a dental professional, and neither you nor the staff will know which treatment you are receiving to ensure fairness. Throughout the study, your mouth and throat will be assessed daily for any signs of pain or sores. This research aims to find better ways to manage the discomfort often experienced during HSCT, making the journey easier for patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients with indication for allogeneic HSCT;
  • Patients over 18 years old;
  • Patients with intact oral mucosa on the first day of conditioning (D-7);
  • Patients able to cooperate with treatment;
  • Patients capable of performing the oral hygiene protocol;
  • Patients who agreed to participate in the study through the informed consent form (TCLE) in accordance with Resolution 466/12 of the National Health Council.
  • Exclusion Criteria:
  • Patients who are receiving medication for the treatment and/or prevention of mucositis;
  • Patients who were not previously evaluated and released by INCA's Dentistry section team

About Instituto Nacional De Cancer, Brazil

The Instituto Nacional de Câncer (INCA) in Brazil is a leading national research institution dedicated to cancer prevention, treatment, and control. As a pivotal sponsor of clinical trials, INCA focuses on advancing oncology through innovative research, comprehensive training, and public health initiatives. The institute collaborates with various stakeholders, including healthcare professionals, academic institutions, and international organizations, to enhance cancer care and improve patient outcomes. By fostering a multidisciplinary approach, INCA aims to contribute significantly to the global fight against cancer and support evidence-based practices in oncology.

Locations

Rio De Janeiro, Rj, Brazil

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported